Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.
Cold atmospheric plasma (CAP) is a specific type of partially ionized gas that is less than 104°F at the point of application. It was recently shown that CAP can be used for decontamination and sterilization, as well as anti-cancer treatment. Here, we investigated the effects of CAP on HIV-1 replica...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5081187?pdf=render |
id |
doaj-8aebc6ceb0f04b5b855be35349ef1fae |
---|---|
record_format |
Article |
spelling |
doaj-8aebc6ceb0f04b5b855be35349ef1fae2020-11-25T01:42:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011110e016532210.1371/journal.pone.0165322Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.Olga VolotskovaLarisa DubrovskyMichael KeidarMichael BukrinskyCold atmospheric plasma (CAP) is a specific type of partially ionized gas that is less than 104°F at the point of application. It was recently shown that CAP can be used for decontamination and sterilization, as well as anti-cancer treatment. Here, we investigated the effects of CAP on HIV-1 replication in monocyte-derived macrophages (MDM). We demonstrate that pre-treatment of MDM with CAP reduced levels of CD4 and CCR5, inhibiting virus-cell fusion, viral reverse transcription and integration. In addition, CAP pre-treatment affected cellular factors required for post-entry events, as replication of VSV-G-pseudotyped HIV-1, which by-passes HIV receptor-mediated fusion at the plasma membrane during entry, was also inhibited. Interestingly, virus particles produced by CAP-treated cells had reduced infectivity, suggesting that the inhibitory effect of CAP extended to the second cycle of infection. These results demonstrate that anti-HIV activity of CAP involves the effects on target cells and the virus, and suggest that CAP may be considered for potential application as an anti-HIV treatment.http://europepmc.org/articles/PMC5081187?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Olga Volotskova Larisa Dubrovsky Michael Keidar Michael Bukrinsky |
spellingShingle |
Olga Volotskova Larisa Dubrovsky Michael Keidar Michael Bukrinsky Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells. PLoS ONE |
author_facet |
Olga Volotskova Larisa Dubrovsky Michael Keidar Michael Bukrinsky |
author_sort |
Olga Volotskova |
title |
Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells. |
title_short |
Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells. |
title_full |
Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells. |
title_fullStr |
Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells. |
title_full_unstemmed |
Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells. |
title_sort |
cold atmospheric plasma inhibits hiv-1 replication in macrophages by targeting both the virus and the cells. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Cold atmospheric plasma (CAP) is a specific type of partially ionized gas that is less than 104°F at the point of application. It was recently shown that CAP can be used for decontamination and sterilization, as well as anti-cancer treatment. Here, we investigated the effects of CAP on HIV-1 replication in monocyte-derived macrophages (MDM). We demonstrate that pre-treatment of MDM with CAP reduced levels of CD4 and CCR5, inhibiting virus-cell fusion, viral reverse transcription and integration. In addition, CAP pre-treatment affected cellular factors required for post-entry events, as replication of VSV-G-pseudotyped HIV-1, which by-passes HIV receptor-mediated fusion at the plasma membrane during entry, was also inhibited. Interestingly, virus particles produced by CAP-treated cells had reduced infectivity, suggesting that the inhibitory effect of CAP extended to the second cycle of infection. These results demonstrate that anti-HIV activity of CAP involves the effects on target cells and the virus, and suggest that CAP may be considered for potential application as an anti-HIV treatment. |
url |
http://europepmc.org/articles/PMC5081187?pdf=render |
work_keys_str_mv |
AT olgavolotskova coldatmosphericplasmainhibitshiv1replicationinmacrophagesbytargetingboththevirusandthecells AT larisadubrovsky coldatmosphericplasmainhibitshiv1replicationinmacrophagesbytargetingboththevirusandthecells AT michaelkeidar coldatmosphericplasmainhibitshiv1replicationinmacrophagesbytargetingboththevirusandthecells AT michaelbukrinsky coldatmosphericplasmainhibitshiv1replicationinmacrophagesbytargetingboththevirusandthecells |
_version_ |
1725035532671516672 |